The United States Food and Drug Administration and Prescription Drug Promotion

Ankur S Kalola; Robert Dean

doi:10.19102/icrm.2019.100305

The United States Food and Drug Administration and Prescription Drug Promotion

J Innov Card Rhythm Manag. 2019 Mar 15;10(3):3588-3591. doi: 10.19102/icrm.2019.100305. eCollection 2019 Mar.

Authors

Ankur S Kalola¹, Robert Dean¹

Affiliation

¹ Office of Prescription Drug Promotion, United States Food and Drug Administration, Silver Spring, MD, USA.

Abstract

The impact of prescription drug promotion on health-care professionals (HCPs) is significant. Pharmaceutical industry spending on promotion to HCPs greatly outpaces spending on direct-to-consumer promotion. According to Syneos Health™ PromotionalAnswers, in 2017, the pharmaceutical industry spent more than $24 billion on drug promotion, with more than $18.5 billion allotted for marketing to HCPs. Although prescription drug promotion can provide valuable information about drug therapies, it is essential that it be truthful, balanced, and not misleading, because HCPs may consider this information when making treatment decisions for their patients.

Keywords: Advertising; Food and Drug Administration; Office of Prescription Drug Promotion; prescription drug promotion; promotion.

Publication types

Review